Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial

BACKGROUND: Alcoholic liver disease is the leading cause of cirrhosis worldwide. Due to an increase in alcohol overuse, alcoholic liver disease has become an increased burden on health care systems. Abstinence from alcohol remains the cornerstone of alcoholic liver disease treatment; however, this a...

Descripción completa

Detalles Bibliográficos
Autores principales: Madsen, Bjørn Stæhr, Trebicka, Jonel, Thiele, Maja, Israelsen, Mads, Arumugan, Manimozhiyan, Havelund, Troels, Krag, Aleksander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828001/
https://www.ncbi.nlm.nih.gov/pubmed/29482588
http://dx.doi.org/10.1186/s13063-018-2523-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828001/
https://www.ncbi.nlm.nih.gov/pubmed/29482588
http://dx.doi.org/10.1186/s13063-018-2523-9

Ejemplares similares